José Antonio García Erce: EMA Certifies Plasma from Egypt for EU Use for the First Time
José Antonio García Erce, Director of the Donation Center, Navarre Health Service (Osasunbidea), posted on LinkedIn:
“THE EMA CERTIFIES PLASMA FROM AFRICA AND THE MIDDLE EAST FOR THE FIRST TIME TO MANUFACTURE BLOOD PRODUCTS IN THE EU
Note from today’s Agencia Española de Medicamentos y Productos Sanitarios (AEMPS):
“Egypt has become the first country in the region to have a plasma collection and processing system aligned with the most demanding EU regulatory standards.
The AEMPS has been in charge of coordinating this certification that will mean that this plasma can be imported for the subsequent manufacture of blood products in European territory.
This certification thus contributes to a more diversified, safe and resilient supply chain that will guarantee that Spanish and European patients continue to have access to essential therapies, under the highest levels of quality, safety and efficacy.”
This has been a success for the Spanish company Grifols, which through Grifols Egypt for Plasma Derivatives (GEPD), would have first achieved clinical self-sufficiency in inmunoglobulins, albumins and coagulation factors for bleeding disorders in Egypt, and will now allow them to export their plasma-derived medicines likely from “reasonably compensated” or “presumably partially remunerated” donates to treat patients from European countries that are not self-sufficient. with its current model.
Hopefully, in other countries in Africa or Latin America, successful strategies like this can be developed to be able to give access to these critical and essential products to the general population of these countries with fewer resources, for equity and justice.”
Get more information below:
“La EMA certifica por primera vez plasma procedente de África y Oriente Medio para fabricar hemoderivados en la UE”
“Medicamentos hemoderivados”
“Egypt achieves self-sufficiency in plasma-derived medicines thanks to Grifols”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow